Markets:

Overview

News

Currencies

International

Treasuries

Eli Lilly (NY:LLY)

1,115.68 -5.68 (-0.51%)

Official Closing Price Updated: 7:00 PM EDT, Aug 4, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2

...

25 26 27 28 29 30 31 32 33

...

99 100 Next >

Here's How Much You Would Have Made Owning Eli Lilly Stock In The Last 15 Years ↗

February 18, 2026

Via Benzinga

Eli Lilly's Landmark Trial Shows Major Psoriasis-Obesity Breakthrough With Taltz-Zepbound Combo ↗

February 18, 2026

Eli Lilly's latest trial results and new licensing agreement show promise in treating psoriasis, obesity, and kidney disease.

Via Benzinga

Health Care Sector (XLV) Shows Resilience Amid Tech Volatility and Strong Jobs Data

February 18, 2026

As the broader market grappled with a violent valuation reset in the technology sector, the health care industry emerged as a critical anchor for investors in early 2026. The Health Care Select Sector...

Via MarketMinute

The Trillion-Dollar Pharmaceutical Giant: Eli Lilly Makes History as Weight-Loss Revolution Drives Unprecedented Growth

February 17, 2026

In a historic moment for the global healthcare industry, Eli Lilly and Company (NYSE:LLY) has officially cemented its position as the world’s first pharmaceutical company to surpass a $1 trillion...

Via MarketMinute

Topics Earnings Economy

Eli Lilly & Co (NYSE:LLY) Combines Explosive Growth with a Bullish Technical Setup ↗

February 17, 2026

Via Chartmill

Should You Buy the Vanguard S&P 500 ETF With the Stock Market Near a Record High? History Offers a Clear Answer ↗

February 17, 2026

Despite recent volatility, trends like artificial intelligence could fuel another strong year for the stock market.

Via The Motley Fool

Topics Artificial Intelligence ETFs Stocks

Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash ↗

February 17, 2026

Agios Pharmaceuticals targets rare blood disorders with a marketed anemia drug and a focused clinical-stage pipeline.

Via The Motley Fool

Topics Regulatory Compliance

Cogent Biosciences Stock Soars 346% in a Year, but One Fund Just Sold Off $4.5 Million ↗

February 17, 2026

This biotech firm develops precision therapies targeting rare genetic diseases, with a lead candidate focused on oncology indications.

Via The Motley Fool

Topics Regulatory Compliance

Structure Therapeutics Stock Up 187% in One Year as Fund Trims $8 Million From Stake ↗

February 17, 2026

Structure Therapeutics develops oral therapies for chronic diseases, using a proprietary platform to target G-protein-coupled receptors.

Via The Motley Fool

Kymera Therapeutics Stock Up 120% in 1 Year as Fund Adds $3 Million More ↗

February 17, 2026

Kymera Therapeutics develops targeted protein degradation therapies for immunology and oncology, advancing multiple clinical-stage programs.

Via The Motley Fool

1 Reason I'd Buy Eli Lilly Stock and Never Sell ↗

February 17, 2026

A robust pipeline is essential for a buy-and-hold pharmaceutical stock.

Via The Motley Fool

Topics Intellectual Property

The Biotechnology Renaissance: AI and Capital Collide in a Multi-Trillion Dollar Pivot

February 17, 2026

As of February 17, 2026, the biotechnology sector is undergoing its most significant structural transformation in decades, a period now widely termed the "Biotechnology Renaissance." Following a...

Via MarketMinute

Topics Artificial Intelligence Economy Initial Public Offering

NVO Stock Generates Retail Buzz After European Commission Approves 7.2 MG Once-Weekly Dose Of Wegovy Injection ↗

February 17, 2026

The approval follows a positive recommendation from the European Medicines Agency and is supported by data from clinical trials involving more than 1,400 participants.

Via Stocktwits

Topics Lawsuit

Hims & Hers Faces New Hurdle In Weight-Loss Brawl With Novo Nordisk ↗

February 17, 2026

Novo Nordisk and the FDA are both mounting pressure on Hims & Hers Health and other GLP-1 compounders.

Via Investor's Business Daily

Topics Lawsuit

2026 Could Be a Big Year for Viking Therapeutics. Time to Buy? ↗

February 17, 2026

Viking should have plenty of news to share with investors this year.

Via The Motley Fool

Eli Lilly's Experimental Cancer Drug Cuts Recurrence Risk In Early-Stage Lung Cancer Patients ↗

February 17, 2026

Eli Lilly's lung cancer trial shows lower recurrence risk and strong survival benefit in early-stage patients.

Via Benzinga

Nasdaq, S&P 500 Futures Lower As AI Disruption Fears Linger: Why AAPL, ZIM, OCUL, NCLH Are On Traders' Radar Today ↗

February 17, 2026

Wall Street resumed trade after the Presidents’ Day break to find a market still grappling with the ‘AI disruption’ trade.

Via Stocktwits

Topics Artificial Intelligence ETFs Economy

Novo Nordisk's New Diabetes Drug Outshines Ozempic: Is The Stock a Buy? ↗

February 16, 2026

Novo Nordisk's plan to gain ground in the GLP-1 space is slowly taking shape.

Via The Motley Fool

Liberty One Cuts Its Lamb Weston Position in Half With $32 Million Sale ↗

February 16, 2026

Lamb Weston is a global leader in frozen potato products, serving both retail and foodservice markets with a diversified brand portfolio.

Via The Motley Fool

Topics Economy Regulatory Compliance Supply Chain

Forget AI Stocks: This Pharma Giant Is Using AI to Dominate Drug Discovery ↗

February 15, 2026

And there's more than one way to monetize this technology.

Via The Motley Fool

Topics Artificial Intelligence

The Smartest Growth ETF to Buy With $1,000 Right Now. (Hint: It Has Averaged Annual Gains of 18.6% Over the Past 10 Years.) ↗

February 15, 2026

It's an easy way to quickly own 150-plus companies growing at a solid clip.

Via The Motley Fool

Topics ETFs

Eli Lilly Just Delivered Great News for Investors -- and It Goes Beyond Weight-Loss Drugs ↗

February 15, 2026

Eli Lilly isn't a one-trick pony.

Via The Motley Fool

What Is One of the Best Pharmaceutical Stocks to Own for the Next 10 Years? ↗

February 14, 2026

Eli Lilly continues to pursue smart acquisitions for the long term.

Via The Motley Fool

Topics Intellectual Property

Got $500? 2 Pharma Stocks to Buy and Hold Forever. ↗

February 14, 2026

Growth, value, or both?

Via The Motley Fool

Novo Nordisk To Meet Wegovy Pill Demand In US Before Expanding To Avoid Supply Shortage, Says CEO Doustdar ↗

February 13, 2026

Novo is looking to ensure the U.S. market is supplied before choosing another country to scale in, Doustdar said in an interview with CNBC.

Via Stocktwits

Topics Lawsuit

"Blowout" Jobs Report Ignites 2026 Growth Hopes as Unemployment Hits 4.3% Floor

February 13, 2026

The U.S. labor market kicked off 2026 with an unexpected surge, as the January nonfarm payrolls report shattered analyst expectations and provided a much-needed jolt to the economic outlook. Adding...

Via MarketMinute

Topics Artificial Intelligence Economy Workforce

Hospitals Stand Tall: Healthcare Sector Becomes Safe Haven Amid "Warsh Shock" and Tech Volatility

February 13, 2026

In a day defined by sharp reversals and a fundamental recalibration of market leadership, the healthcare sector emerged as the primary beneficiary of a massive capital rotation on February 13, 2026....

Via MarketMinute

Topics Artificial Intelligence Earnings Economy

Did Eli Lilly Just Make a Deal for Its Next Blockbuster Drug? ↗

February 13, 2026

Eli Lilly announced an acquisition of an innovative new autoimmune drug.

Via The Motley Fool

The Great 2026 Divergence: Tech Titans Rise on AI Execution While Healthcare Reaps a Regulatory Whirlwind

February 13, 2026

As the opening bell rang on February 13, 2026, the divergence between the U.S. technology and healthcare sectors reached a historic fever pitch, signaling a fundamental shift in how markets price...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Meet the 6.3% Yield Dividend Stock That Could Soar in 2026 ↗

February 13, 2026

Pfizer's long-acting GLP-1 weight loss candidate could set the stage for a stock rally.

Via The Motley Fool

Topics Intellectual Property

< Previous 1 2

...

25 26 27 28 29 30 31 32 33

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.